Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/24617Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Charalabopoulos, K. | en |
| dc.contributor.author | Gogali, A. | en |
| dc.contributor.author | Dalavaga, Y. | en |
| dc.contributor.author | Daskalopoulos, G. | en |
| dc.contributor.author | Vassiliou, M. | en |
| dc.contributor.author | Bablekos, G. | en |
| dc.contributor.author | Karakosta, A. | en |
| dc.contributor.author | Constantopoulos, S. | en |
| dc.date.accessioned | 2015-11-24T19:42:17Z | - |
| dc.date.available | 2015-11-24T19:42:17Z | - |
| dc.identifier.issn | 1812-9269 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/24617 | - |
| dc.rights | Default Licence | - |
| dc.subject | Aged | en |
| dc.subject | Aged, 80 and over | en |
| dc.subject | Cadherins/*blood | en |
| dc.subject | Carcinoma, Non-Small-Cell Lung/*pathology | en |
| dc.subject | Female | en |
| dc.subject | Humans | en |
| dc.subject | Lung Neoplasms/*pathology | en |
| dc.subject | Male | en |
| dc.subject | Middle Aged | en |
| dc.subject | Prognosis | en |
| dc.subject | Smoking | en |
| dc.subject | Tumor Markers, Biological/blood | en |
| dc.title | The clinical significance of soluble E-cadherin in nonsmall cell lung cancer | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/16614715 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2006 | - |
| heal.abstract | AIM: Aberrant expression of the epithelial transmembrane adhesion molecule E-cadherin (E-cad) has been associated with many human malignancies. In the present study the clinical significance of serum levels of soluble E-cadherin (sE-cad) in newly diagnosed patients with non small cell lung cancer (NSCLC) was investigated. MATERIAL AND METHODS: An enzyme linked immunospecific assay (ELISA) to determine the circulating levels of sE-cad in 20 newly diagnosed patients with NSCLC as well as in 29 healthy volunteers (control group) was used. RESULTS: NSCLC patients exerted increased circulating levels of sE-cad compared with individuals of the control group (p < 0.001). An association was also detected between serum sE-cad levels and the development of distant metastases. On the contrary, no statistically significant correlation could be established with histological type, gender and smoking habits. Patients with increased sE-cad levels at diagnosis had worser outcome, although multivariate analysis failed to demonstrate that sE-cad levels represent an independent prognostic factor of survival. CONCLUSION: Our data suggest that E-cad plays a role in the pathogenesis of NSCLC. sE-cad levels may be further studied as a potential prognostic biomarker. | en |
| heal.journalName | Exp Oncol | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Daskalopoulos-2006-the clinical significance.pdf | 116.03 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
